ABCL vs ADMA Stock Comparison

ADMA currently leads ABCL in this stock comparison, with AIQ scores of 78 vs 64. The clearest difference is value.

Market data as of Nov 15, 2026 market close· AIQ score gap 14 points
ABCL
Healthcare
vs
ADMA
Healthcare
ABCL
AbCellera Biologics Inc.
Price
$11.49
Day move
-1.12%
AIQ Score
64/100
Best edge
Balanced
Sector
Healthcare
ADMA
ADMA Biologics, Inc.
Leads
Price
$13.68
Day move
+3.32%
AIQ Score
78/100
Best edge
Value
Sector
Healthcare

What is the main difference between ABCL and ADMA?

ADMA leads the current stock comparison as ADMA Biologics, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

AbCellera Biologics Inc. vs ADMA Biologics, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictStableAIQ Comparison Conviction 8/10

ADMA leads

ADMA leads by 14 AIQ points, primarily on Value and Risk Resilience, and the lead has widened from 7 points over 30 sessions. Wall Street currently favors ABCL on target upside.

Stable: 5 of 6 evidence groups support ADMA, its lead is widening, and its current signal state is conflicted.

Evidence agreement: 5 of 6Comparison trend: Strengthening
ABCL

AbCellera Biologics Inc.

AIQ Score
64/100
AIQ Edge Score
7/10
ADMA

ADMA Biologics, Inc.

Leads
AIQ Score
78/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors ADMA over ABCL, 78 versus 64 as of Nov 15, 2026. ADMA's advantage is driven primarily by stronger value and risk resilience. ADMA also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors ABCL. 5 of 6 covered evidence groups favor ADMA today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. ADMA lead: Strengthening — the AIQ differential moved from 7 to 14 points over 30 sessions.

Compare AbCellera Biologics Inc. and ADMA Biologics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

ABCL
-22.5%
ADMA
+812.0%

Price return comparison

Growth of $10,000, price only

ABCL $7,753 · ADMA $91,200

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare ABCL and ADMA against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

ABCL advantage
0
ADMA advantage
  • Value47 vs 80
    ADMA +33
  • Risk Resilience34 vs 56
    ADMA +22
  • Quality61 vs 72
    ADMA +11
  • Momentum89 vs 91
    Even

5 of 6 evidence groups favor ADMA. ADMA’s edge is concentrated in value and risk resilience.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

ABCL+1 AIQ

Largest factor move: Momentum +2

No signal started or stopped since the prior session; its 4 active signals are unchanged.

ADMA0 AIQ

No factor moved materially.

New signals

  • RSI Overbought — bearish, momentum, short horizon

ADMA's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — ABCL and ADMA both carry a full feed there.

The central trade-off

ADMA (ADMA Biologics, Inc.): the stronger current systematic profile, led by value and risk resilience.

ABCL (AbCellera Biologics Inc.): the counter-case, on analyst expectations.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

ADMA

ADMA on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

ABCL

ABCL on combined revenue and EPS growth.

Value

ADMA

ADMA on the peer-relative Value factor, by 33 points.

Momentum

Even

The two are level on Momentum.

Lower downside

ADMA

ADMA on Risk Resilience, by 22 points.

Analyst upside

ABCL

ABCL on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors ADMA, analyst targets favor ABCL. That disagreement is the most useful thing on this page.

MeasureABCLADMANote
Implied upside to target+50.9%+31.6%ABCL has more room
Target dispersion+46.2%0%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering134Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

5 of 6 covered evidence groups favor ADMA. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreADMA64 vs 78
FundamentalsADMAon balancerevenue growth 162.7% vs 13.4%; EPS growth 27.8% vs 29.4%; TTM ROE -3.8% vs 11.4%; gross margin 75.6% vs 68.5%; operating margin -298% vs 44.9% — ADMA takes 3 of 5 decided legs, not all of them
ValuationADMAValue 47 vs 80
TechnicalsADMAPrice vs 50-day -6.9% vs 29.4%; vs 200-day 58.8% vs 27.6%
Risk ResilienceADMARisk Resilience 34 vs 56
Analyst expectationsABCLTarget upside 50.9% vs 31.6%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ABCL and ADMA and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 14 points. (supports the conclusion holding)
  • 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
  • The leader's advantage has been widening. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ADMA.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

ADMA lead: Strengthening — the AIQ differential moved from 7 to 14 points over 30 sessions.

May 27ABCL leads above the line · ADMA leads belowNov 13
Today
ADMA +14
64 vs 78
7 sessions ago
ADMA +15
62 vs 77
30 sessions ago
ADMA +7
62 vs 69
90 sessions ago
ABCL +8
64 vs 56

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

ABCLConflicted

1 bullish / 2 bearish / 1 neutral, conflicted

Only ABCL

  • Golden Cross Active — bullish, trend, long horizon (70.46%)
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
ADMAConflicted

3 bullish / 2 bearish / 2 neutral, conflicted

Only ADMA

  • Death Cross Active — bearish, trend, long horizon (1.42%)
  • ADX Trend Strengthening — neutral, trend, medium horizon
  • Keltner Channel Breakout — bullish, volatility, short horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • RSI Overbought — bearish, momentum, short horizon
  • TRIX Bullish Signal — bullish, momentum, short horizon

Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.

ADMA leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

ABCLDivergence

Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -1.12%, AIQ +1 points).

ADMANo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +3.32%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1ABCL closes the Value gap — currently 33 points behind, the largest single contributor to ADMA's edge.
  2. 2ABCL's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3ADMA's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

ADMA leads on balance
MetricABCLADMA
Revenue growth (YoY)162.7%13.4%
EPS growth (YoY)27.8%29.4%
Gross margin75.6%68.5%
Operating margin-298%44.9%
Return on equity (TTM)-3.8%11.4%
Debt to equity0.130.46

Performance

Split across windows
MetricABCLADMA
1 week (5 sessions)-3.3%7.5%
1 month (20 sessions)-2.6%28.1%
3 months (63 sessions)2.6%46.5%
6 months (126 sessions)180.9%65.4%
Year to date236%-25%
1 year (252 sessions)189.4%-16.9%

Technicals

ADMA has the stronger structure
MetricABCLADMA
RSI (14)45.271
ADX (14)11.934
Price vs 50-day-6.9%29.4%
Price vs 200-day58.8%27.6%
Volatility (1M, annualized)88.8%102.3%

Risk

ADMA is the more resilient
MetricABCLADMA
Beta2.42-0.09
Sharpe ratio1.73-0.01
Sortino ratio3.02-0.01
Max drawdown-40.1%-62.7%
Current drawdown-22.5%-32.9%
Annualized volatility85.3%58.9%
Value at risk (95%)-7.1%-4.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, ABCL or ADMA?

On the Algovestiq AIQ Score, ADMA is the stronger of the two as of Nov 15, 2026, scoring 78 against ABCL's 64. The edge comes from value and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is ABCL or ADMA the better buy right now?

ADMA carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor ADMA over ABCL?

The composite weights Quality, Value, Momentum and Risk Resilience. ADMA leads Value by 33 points; ADMA leads Risk Resilience by 22 points; ADMA leads Quality by 11 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, ABCL or ADMA?

Analyst price targets imply +50.9% upside for ABCL and +31.6% for ADMA, so the Street currently favors ABCL. That points the opposite way to the AIQ Score, which favors ADMA. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, ABCL or ADMA?

ADMA is the better-valued of the two on the peer-relative Value factor. ADMA on the peer-relative Value factor, by 33 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, ABCL or ADMA?

ABCL on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, ABCL or ADMA?

The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, ABCL or ADMA?

ADMA is the more resilient of the two, so the other name carries the higher downside risk. ADMA on Risk Resilience, by 22 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is ABCL more profitable than ADMA?

The profitability evidence is mixed: gross margin 75.6% vs 68.5%; operating margin -298% vs 44.9%; ttm roe -3.8% vs 11.4%. ABCL leads on one measure and ADMA on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is ADMA's lead over ABCL getting stronger or weaker?

ADMA lead: Strengthening — the AIQ differential moved from 7 to 14 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the ABCL vs ADMA verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ABCL closes the Value gap — currently 33 points behind, the largest single contributor to ADMA's edge; ABCL's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; ADMA's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about ABCL and ADMA?

ABCL: 1 bullish / 2 bearish / 1 neutral, conflicted. ADMA: 3 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ABCL is Golden Cross Active (bullish, long horizon). On ADMA it is Death Cross Active (bearish, long horizon).

Compare ABCL and ADMA with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.